 |
The following information is NOT intended to endorse drugs or recommend therapy. While these reviews might be helpful, they are not a substitute for the expertise, skill, knowledge and judgement of healthcare practitioners in patient care.
Learn more about Torisel.
No reviews have yet been submitted. Be the first to review this drug.
-Results Support Planned, Randomized Phase 3 ADAPT Study- DURHAM, N.C., Feb. 4, 2012 /PRNewswire/ -- Argos Therapeutics Inc. today announced that...
14.7 months median progression free survival 28% confirmed partial response rate & 72% disease control rate at week 16 SOUTH SAN FRANCISCO,...
-High Resolution Immune Monitoring Analysis Shows AGS-003 in Combination With Sunitinib Overcomes Immuno-Suppressive Environment of RCC and Induces...
The U.S. Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not...
Inlyta (axitinib) has been approved by the U.S. Food and Drug Administration to treat advanced renal cell carcinoma in people who haven't responded to another...
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines & natural products. This material is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Data sources include Micromedex™ (updated Jan 27th, 2011), Cerner Multum™ (updated Jan 3rd, 2012), Wolters Kluwer™ (updated Jan 31st, 2012) and others.
To view content sources and attributions, refer to our editorial policy.
Copyright © 2000-2012 Drugs.com. All rights reserved.
We comply with the HONcode standard for trustworthy health information.
Verify here
